Clinical Trials Sponsored by Xeris Pharmaceuticals

Total 19696 results

Xeris Pharmaceuticals

Completed

Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D

Diabetes Mellitus, Type 1 | Insulin-dependent Diabetes Mellitus

United States
Xeris Pharmaceuticals

Active, not recruiting

Study of XP-8121 For the Treatment of Adult Subjects With Hypothyroidism

Hypothyroidism

United States
Xeris Pharmaceuticals

Completed

Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D

Hypoglycemia

Canada
Xeris Pharmaceuticals

Completed

Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

Hyperinsulinemic Hypoglycemia

United States
Xeris Pharmaceuticals

Completed

G-Pen™ for Hypoglycemia Rescue in T1D Patients

Hypoglycemia

United States
Xeris Pharmaceuticals

Completed

Safety and Efficacy of G-Pen Compared to Lilly Glucagon for Hypoglycemia Rescue in Adult Type 1 Diabetics

Hypoglycemia | Diabetes Mellitus, Type 1

United States, Canada
Xeris Pharmaceuticals
Empiristat, Inc.

Completed

G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus | Severe Hypoglycemia | Insulin Hypoglycemia

United States, Canada, Austria
Xeris Pharmaceuticals
Integrated Medical Development

Terminated

Glucagon Infusion in T1D Patients With Recurrent Severe Hypoglycemia: Effects on Counter-Regulatory Responses

Diabetes Mellitus, Type 1 | Hypoglycemia Unawareness

United States
Xeris Pharmaceuticals
The Emmes Company, LLC

Completed

Glucose Response of G-Pen (Glucagon Injection) in Pediatric T1D Patients

Diabetes Mellitus, Type 1

United States
Xeris Pharmaceuticals
SGS S.A.; Integrated Medical Development

Completed

G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes

Type 1 Diabetes Mellitus | Severe Hypoglycemia | Insulin Hypoglycemia

United States, Canada
Oregon Health and Science University
Xeris Pharmaceuticals

Completed

Three Way Crossover Closed Loop Study With Xeris Glucagon

Type1diabetes

United States
Jaeb Center for Health Research
Xeris Pharmaceuticals

Completed

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Jaeb Center for Health Research
Xeris Pharmaceuticals

Completed

Mini-Dose Glucagon to Treat Non-Severe Hypoglycemia

Diabetes Mellitus, Type 1

United States
Aeris Therapeutics

Terminated

Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema (CV+/-)

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Withdrawn

Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema

Emphysema | Chronic Obstructive Pulmonary Disease (COPD)
Aeris Therapeutics

Completed

Biologic Lung Volume Reduction (BLVR) Phase 2 Homogeneous Study

Homogeneous Emphysema

United States
Aeris Therapeutics

Completed

Israeli Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

Israel
Aeris Therapeutics

Withdrawn

Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Advanced Upper Lobe Predominant (ULP) Emphysema

Advanced Upper Lobe Predominant Emphysema
Aeris Therapeutics

Completed

US 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study - Initial Formulation

Pulmonary Emphysema

United States
Aeris Therapeutics

Terminated

Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) (ASPIRE)

Pulmonary Emphysema

United States, Spain, France, Israel, Netherlands, Greece, Italy
Aeris Therapeutics

Completed

US Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Chronic Obstructive Pulmonary Disease | Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

AeriSeal® System for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | COPD

Israel
Aeris Therapeutics

Terminated

A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema

Lung Diseases | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease(COPD)

Israel
Aeris Therapeutics

Terminated

Post Market Registry Study of the AeriSeal System

Pulmonary Emphysema

Germany, Israel
Aeris Therapeutics

Terminated

A Registry Study of the AeriSeal® System or Lung Volume Reduction in Patients With Advanced Emphysema

Emphysema | Chronic Pulmonary Obstructive Disease

Germany, Israel, Austria, France
Aeris Therapeutics

Completed

AeriSeal System for Lung Volume Reduction

Lung Diseases | Emphysema | Pulmonary Emphysema | Chronic Obstructive Pulmonary Disease (COPD)

Israel, Austria, France, Germany
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 2 Emphysema Study

Pulmonary Emphysema

United States
Aeris Therapeutics

Completed

A Dose Ranging Study of the Aeris Polymeric Lung Volume Reduction (PLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema

Advanced Emphysema

Germany
Aeris Therapeutics

Terminated

Netherlands 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Netherlands
Aeris Therapeutics

Terminated

Israeli 10 mL Bronchoscopic Lung Volume Reduction (BLVR) Phase 1/2 Emphysema Study - Initial Formulation

Pulmonary Emphysema

Israel
Aeris Therapeutics

Completed

US 10 mL Biologic Lung Volume Reduction (BLVR) Phase 1 Emphysema Study

Pulmonary Emphysema

United States
Xeras Medical Technologies

Completed

Study Comparing GAP-Flex to CPM Therapy in Treatment of TKR (GAP-Flex)

Total Knee Replacement

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Hypoglycemia in Post-Bariatric Surgery Patients

Hypoglycemia | Complications of Bariatric Procedures

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Completed

CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

Congenital Hyperinsulinism

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...

Completed

PK/PD Study With G-Pump (Glucagon Infusion) in T1DM Patients

Hypoglycemia

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...

Completed

Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia

Hypoglycemia

United States
Xeris Pharmaceuticals
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Emissary...

Completed

Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes

Hypoglycemia

United States
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Extension Study of 1.0mg Dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Novartis Pharmaceuticals
Chugai Pharmaceutical

Completed

Study of High-dose Letrozole Therapy in Postmenopausal Patients With Breast Cancer

Postmenopausal Women With Advanced Breast Cancer

Japan
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Terminated

Study to Evaluate Arthroplasty Specimens for Osteoarthritis of the Knee and Hip

Osteoarthritis, Knee | Osteoarthritis, Hip

United States, Poland, United Kingdom
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response

Hepatitis C

Belgium, United States, Puerto Rico, Netherlands
Regeneron Pharmaceuticals
Teva Pharmaceutical Industries, Ltd.

Completed

To Assess the Patients' Ability to Self-Administer Fasinumab (FACT DEVICE)

Osteoarthritis, Knee | Osteoarthritis, Hip

United States
Alexza Pharmaceuticals, Inc.
Pharmaceutical Research Associates

Unknown

Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder

Agitation,Psychomotor

United States
Enanta Pharmaceuticals, Inc
Pharmaceutical Research Associates

Completed

Drug-Drug Interaction Study Between EDP-938, Cyclosporine and Prednisone in Healthy Adult Subjects

RSV Infection

United States
Vertex Pharmaceuticals Incorporated
Tibotec Pharmaceutical Limited

Completed

Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV

HIV Infections | Hepatitis C

France, Spain, United States, Germany
Tibotec Pharmaceuticals, Ireland
Tibotec Pharmaceutical Limited

Completed

A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents (DIONE)

HIV-1 Infection

France, United States, Spain, Ukraine, United Kingdom, Ireland
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics Study of TNO155 in Participants With Mild, Moderate, or Severe Renal Impairment Compared to Matched Healthy Participants

Renal Impairment
Novartis Pharmaceuticals
Pharmaceutical Research Associates

Withdrawn

Pharmacokinetics of TNO155 in Participants With Mild, Moderate, or Severe Hepatic Impairment Compared to Matched Healthy Participants

Hepatic Impairment

Clinical Trials Sponsored by Xeris Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations